This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
- Investigator
- Ilyas Sahin
- Ages
- 18 Years - N/A
- Sexes
- All